Epidemiology of Acromegaly in Denmark 1991-2010
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01752621|
Recruitment Status : Unknown
Verified December 2014 by University of Aarhus.
Recruitment status was: Active, not recruiting
First Posted : December 19, 2012
Last Update Posted : December 8, 2014
|Condition or disease|
Background: Acromegaly is a rare disease caused by GH hypersecretion from a pituitary adenoma. The annual incidence is estimated to be 3-5/million with a prevalence of 100 - 150/million. The incidence rate is however uncertain since no nationwide surveys exist. If left untreated or poorly controlled the condition is associated with progressive morbidity and an excess mortality. The primary treatment is surgery, which however only provides a cure rate of ≈ 50 -60% due to the size of the tumour. The second line treatment today is medical treatment with slow release formulations of somatostatin analogs (SA) and, more recently, a specific GH antagonist.
Accurate data on incidence rates and outcome of treatment are of obvious importance in order to provide optimal and evidence-based treatment for the disease. This is particularly relevant in light of the availability of new and effective treatment modalities such as the GH antagonist, the proper place of which in the treatment algorithm still remains controversial.
Denmark holds a unique position in terms of epidemiological studies due to the existence of well organized databases which include all its inhabitants. A recognised problem with epidemiological surveys from specialised centres is whether the figures are representative for the general population. A nationwide Danish study will profit from the fact that every Danish citizen holds a unique ID number that makes it easy to retrieve and combine pertinent data regarding health, disease and death from different registries. The investigators have previously used this for a landmark survey of another rare endocrine disease, i.e. Cushing's syndrome. This publication has been cited more than 100 times.
Aim: To assess the incidence rate, morbidity and mortality of acromegaly in Denmark.
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Observational Model:||Case Control|
|Official Title:||Incidence and Late Prognosis of Acromegaly in Denmark From 1991 - 2010: Twenty Years of Medical Treatment|
|Study Start Date :||February 2013|
|Estimated Primary Completion Date :||March 2015|
|Estimated Study Completion Date :||March 2015|
patients with acromegaly
matched background population
- Mortality of acromegaly [ Time Frame: 3 years ]Mortality and morbidity of acromegaly (MRR)
- • Incidence of Acromegaly [ Time Frame: 3 years ]• Incidence of Acromegaly
- prevalence rates of Acromegaly [ Time Frame: 3 years ]prevalence rates of Acromegaly
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01752621
|Aarhus University Hospital|
|Aarhus, Denmark, 8000|
|Aarhus, Denmark, 8000|
|Study Director:||Jens Otto Jorgensen, professor||MEA AUH|